Clinical Development of new antiretroviral agents
Treatment of Multi drug Resistant HIV virus, HIV-HCV co-infection
Suboxone Clinic for HIV infected opioid-addicted patients
Selected Publications
Mounzer K, Slim J, Ramgopal M, Hedgcock M, Bloch M, Santana J, Mendes I, Guo Y, Arora P, Montezuma-Rusca JM, Sklar P, Baeten JM, Segal-Maurer S.: Efficacy and Safety of Switching to Daily Bictegravir Plus Lenacapavir From a Complex Human Immunodeficiency Virus Treatment Regimen: A Randomized, Open-Label, Multicenter Phase 2 Study (ARTISTRY-1). Clin Infect Dis Nov 2024.
Maguire C, Rueve K, Farmer E, Huesgen E, Karaj A, Binkley A, Mounzer K, Brizzi M, Chary P, Sung P, Graziani A, Hiserodt E, Baron J, Koenig H, Short WR.: Real world virologic outcomes in patients with elevated body mass index receiving long acting cabotegravir/rilpivirine. Clin Infect Dis Nov 2024.
Kelley CF, Acevedo-Quiñones M, Agwu AL, Avihingsanon A, Benson P, Blumenthal J, Brinson C, Brites C, Cahn P, Cantos VD, Clark J, Clement M, Creticos C, Crofoot G, Diaz RS, Doblecki-Lewis S, Gallardo-Cartagena JA, Gaur A, Grinsztejn B, Hassler S, Hinojosa JC, Hodge T, Kaplan R, Lacerda M, LaMarca A, Losso MH, Valdez Madruga J, Mayer KH, Mills A, Mounzer K, Ndlovu N, Novak RM, Perez Rios A, Phanuphak N, Ramgopal M, Ruane PJ, Sánchez J, Santos B, Schine P, Schreibman T, Spencer LY, Van Gerwen OT, Vasconcelos R, Vasquez JG, Zwane Z, Cox S, Deaton C, Ebrahimi R, Wong P, Singh R, Brown LB, Carter CC, Das M, Baeten JM, Ogbuagu O; PURPOSE 2 Study Team.: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons. N Engl J Med Nov 2024.
apasavvas E, Lu L, Fair M, Oliva I, Cassel J, Majumdar S, Mounzer K, Kostman JR, Tebas P, Bar-Or A, Muthumani K, Montaner LJ.: Cloning and functional characterization of novel human neutralizing anti-interferon-alpha and anti-interferon- J Immunol. Sept 2024.
Livio Azzoni, Ian Tietjen, Qin Liu, Shalini Singh, Mansi Purwar, Matthew Fair, Paridhima Sharma, Leila B. Giron, Jianyi Ding, Linden Lalley-Chareczko, Emily Hiserodt, Karam Mounzer, David B. Weiner, Mohamed Abdel-Mohsen, Luis J. Montaner: Prior COVID-19 Alters Antibody Function in ART-Suppressed PWH Receiving SARS-CoV-2 Vaccination. CROI 2024.
Francesco E. Marino, Maxime Bellefroid, Ryan Krause, Marie Armani-Tourret, Suvadip Mallick, Emmanouil Papasavvas, Matthew Fair, Karam Mounzer, Pablo Tebas, Luis J. Montaner, Mathias Lichterfeld, Katharine J. Bar: Autologous Neutralizing Antibodies Contribute to Virus Control in a Subset of PWH Treated With bNAbs. CROI 2024.
Anthony M. Mills, MD, Laurence Brunet, PhD, Kevin R. Frost, BM
Gerald Pierone, MD, Jr.
Michael G. Sension, MD
Philip C. Lackey, MD
Karam Mounzer, MD:
Michael B. Wohlfeiler, JD, MD,
Jennifer S. Fusco, BS:
Carolyn A. Brown, MSPH, PhD: ViiV Healthcare/GSK: Stocks/Bonds (Public Company)
Vani Vannappagari, MBBS, MPH, PhD:
Michael Aboud, MBChB, MRCP:
Piotr Budnik, MBBCh FCP(SA):
Gregory P. Fusco, MD, MPH
: Cabotegravir Long-Acting for Pre-Exposure Prophylaxis (PrEP): Real World Data on On-Time Dosing, HIV Testing and HIV Acquisition from the OPERA Cohort. ID WEEK 2024.
EMMANOUIL PAPASAVVAS, Jessicamarie Morris, Brian N. Ross, Matthew Fair, Livio Azzoni, Karam Mounzer, Jay R. Kostman, Pablo Tebas, Luis J. Montaner: Lower ADCC After 26 Weeks of PEG-IFN-α2b and 2 bNAbs in Otherwise Suppressed HIV-1+ CROI 2024.
Anthony Mills, Laurence Brunet, Karam Mounzer, Michael B. Wohlfeiler, Kevin R. Frost, Ricky K. Hsu, Gerald Pierone, Michael Sension, Philip C. Lackey, Jennifer S. Fusco, Carolyn Brown, Vani Vannappagari, Michael Aboud, Piotr Budnik, Gregory P. Fusco: Preexposure Prophylaxis With Cabotegravir Long-Acting Injectable in the OPERA Cohort. CROI 2024.
Karam Mounzer, Laurence Brunet, Michael Sension, Ricky K. Hsu, Jennifer S. Fusco, Yohance O. Whiteside, Gregory P. Fusco
: Weight Change After Starting Doravirine Among ART-Experienced Individuals in the US. CROI 2024.
back to top
Last updated: 02/03/2025
The Trustees of the University of Pennsylvania
